Charles Swanton completed his MDPhD in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK, followed by a clinical science/medical oncology training in 2008. He combines his laboratory research at the Francis Crick Institute with clinical duties focused on biological mechanisms of cancer drug resistance.
Professor Swanton was made Fellow of the Royal College of Physicians in April 2011 and Chair in Personalised Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011.
He is also the Chief Investigator of the CR-UK TRACERx lung cancer evolution study and co-directs the CRUK Lung Cancer Centre of Excellence.
Professor Swanton was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013 and appointed Fellow of the European Academy of Cancer Sciences in 2013 and Fellow of the Academy of Medical Sciences in 2015.
He was awarded the Jeremy Jass Prize (2014), Stand up to Cancer Translational Cancer Research Prize (2015), Glaxo Smithkline Biochemical Society Prize in recognition of distinguished research leading to new advances in medical science, and the Ellison-Cliffe Medal and Lecture, Royal Society of Medicine (2017).
Professor Swanton was appointed Napier Professor in Cancer by the Royal Society in 2016.
He has been a member of the ESMO Translational Research & Personalised Medicine Working Group and a member of the ESMO Cancer Research Faculty Group since 2015, and an Associate Editor of Annals of Oncology since 2014.
ESMO 2017 Congress
"The Translational Research Track will provide a comprehensive overview of emerging drivers of cell to cell heterogeneity and genome instability that foster diversity and ultimately enable selection and adaptive evolution of cancer subclones"
Charles Swanton was the Translational Research Track Co-Chair of the ESMO 2017 Congress, which took place in Madrid, Spain (8-12 September 2017).